INTRODUCTION
Neoadjuvant chemotherapy represents an option for patients with early breast cancer when an indication for chemotherapy is given. 1 Pathologic complete response (pCR) has predicted long-term outcome in several neoadjuvant studies and is therefore a potential surrogate marker for survival. 2, 3 However, selected trials comparing different neoadjuvant regimens have failed to demonstrate an association between pCR rate and improved outcome. 4 Methodologic limitations are likely to be the reason for this unexpected discrepancy. First, no standardized definition for pCR exists. Some trials have applied the pCR definition to the breast tumor only, whereas others have included the axillary nodes. 5,6 Furthermore, some studies have included the presence of focal invasive cancer 7 or noninvasive cancer residuals in their pCR definition, 6 whereas others have defined pCR as the complete eradication of all invasive and noninvasive cancer. 8 Second, incidence and prognostic impact of pCR vary among JOURNAL OF CLINICAL ONCOLOGY breast cancer-intrinsic subtypes. For example, although patients with luminal A-like breast cancer show a low pCR rate, their overall prognosis is favorable, whereas patients with triple-negative (TN) breast cancer show a high pCR rate but have an unfavorable outcome. 9 Including all intrinsic subtypes might therefore attenuate the prognostic information of pCR.
METHODS

Objectives and End Points
The first aim of this pooled analysis was to compare currently used definitions of pCR and investigate their role in predicting risk of recurrence or death. Individual patient data from case report forms based on local histopathologic assessments allowed evaluation of the following pCR definitions reported in the literature: ypT0 ypN0. No invasive or noninvasive residual in breast or nodes. Used by the German study groups (German Breast Group [GBG] and Arbeitsgemeinschaft Gynäkologische Onkologie-Breast Group [AGO-B]) as part of the Sinn score. 10 ypT0/is ypN0. No invasive residual in breast or nodes; noninvasive breast residuals allowed. Used by MD Anderson Cancer Center, Austrian Breast and Colorectal Cancer Study Group, and Neo-Breast International Group. 6, 11, 12 ypT0/is ypN0/ϩ. No invasive residual in the breast; noninvasive breast residuals and infiltrated lymph nodes allowed. Used by National Surgical Adjuvant Breast and Bowel Project. 5, 13 ypTՅ1mic ypN0/ϩ. No gross invasive residuals in the breast; focal invasive and noninvasive residuals in breast and infiltrated lymph nodes allowed. Used by French groups using the Sataloff index. 7 Therefore, to compare the impact of the components of the definition on prognosis, the following distinct subgroups according to their residual tumor extent after neoadjuvant chemotherapy were used: ypT0 ypN0, ypTis ypN0, ypT0/is ypNϩ, ypT1mic ypN0/ϩ, and ypTϾ1mic ypN0/ϩ (no pCR according to any definition).
We further investigated three residual disease scoring systems to determine whether they could differentiate prognostic subgroups of patients with residual invasive breast cancer: ypT staging system according to TNM 14 ; ypN staging system according to TNM 14 ; and histologic breast regression score (RS) as proposed by Sinn, 10 with RS 4 indicating no viable tumor cell residuals in the breast, RS 3 indicating only noninvasive residuals in the breast, RS 2 indicating only focal (Ͻ 5 mm) invasive residuals in the breast, RS 1 indicating minimal signs of tumor regression, and RS 0 indicating no signs of regression.
The second aim of this analysis was to assess the prognostic relevance of pCR (according to the best definition as identified in the first part of this analysis) in various intrinsic subtypes. Estrogen (ER) and progesterone receptor (PgR) status were considered positive if Ն 10% of cells stained positive or the Remmele score was Ն 3, 15 taking into account the frequency and intensity of the staining. Human epidermal growth factor receptor 2 (HER2) status was assessed by immunohistochemistry (HER2 positivity if the score was 3) or fluorescent in situ hybridization. Intrinsic breast cancer subtypes were determined according to clinicopathologic criteria recently recommended by the St Gallen panelists. 16 Because information on Ki-67 was not available, we used grade to capture cell proliferation. The following definitions were used:
Luminal A-like tumors. ER positive and/or PgR positive, HER2 negative, grade 1 or 2.
Luminal B/HER2-negative-like tumors. ER positive and/or PgR positive, HER2 negative, grade 3.
Luminal B/HER2-positive-like tumors. ER positive and/or PgR positive, HER2 positive, all grades.
HER2-positive (nonluminal) -like tumors. ER negative and PgR negative, HER2 positive, all grades.
TN tumors. ER negative, PgR negative, HER2 negative, all grades. Histologic type, tumor grade, and ER, PgR, and HER2 status were assessed in the primary tumor core biopsy sample by the local pathologist. In 510 patients, missing data for ER and PgR status from pretreatment biopsies were substituted with information available at surgery.
Patients
Between 1998 and 2006, the GBG and AGO-B study groups conducted seven prospective clinical trials that explored neoadjuvant systemic chemotherapy in patients with operable or nonoperable primary breast cancer. The study designs of GeparDuo (NCT00793377), 17 GeparTrio pilot 18 and main study (NCT00544765), 19,20 GeparQuattro (NCT00288002), 8,21 AGO 1, 22 PREPARE (Preoperative Epirubicin Paclitaxel Aranesp Study; NCT00544232), 23,24 and TECHNO (Taxol Epirubicin Cyclophosphamide Herceptin Neoadjuvant; NCT00795899) 25 have been reported in detail in a review. 26 All trials were approved by the relevant ethics committees. All patients provided written informed consent for study participation and data collection.
All seven trials had comparable main eligibility criteria. Diagnosis of invasive breast cancer was histologically confirmed in all patients by core biopsy. Female patients needed to have measurable disease of the breast tumor either by palpation, ultrasound, or mammography. Tumor size had to be at least 2 cm in the majority of trials, except for the AGO1 trial, which only accepted patients with a tumor size of Ն 3 cm, and the most recent Gepar-Quattro trial, which accepted patients with a tumor size Ն 1 cm according to ultrasound measurements. Locally advanced (cT4a-d) and inflammatory breast cancers were eligible for all trials except GeparDuo. In patients with bilateral disease, the largest tumor was evaluated for response. For the Techno study, only patients with HER2-positive disease were eligible. Patients with primary metastatic disease, other prior malignancies, or prior treatment for invasive breast cancer were excluded in all trials.
All seven trials used chemotherapy with anthracyclines and taxanes. Only patients who received at least one cycle of systemic treatment were included in the analysis. In the GeparQuattro and Techno studies, patients with HER2-positive tumors (n ϭ 622) received trastuzumab simultaneously with neoadjuvant chemotherapy as well as postoperatively to complete 1 full year of treatment. Patients with ER-and/or PgR-positive tumors should receive adjuvant endocrine treatment for at least 5 years. Adjuvant radiotherapy was recommended for patients who underwent breast-conserving surgery as well for patients underwent mastectomy but had initial stage cT3, cT4, cN2, or cN3 disease according to national guidelines.
Statistics
Individual patient data regarding baseline characteristics, histopathologic results at surgery, and follow-up were extracted for this pooled analysis from the original databases from all 6,377 patients participating in these trials. As defined in the protocols, patients with missing data for histologic response were counted as having no response.
Baseline parameters were correlated with pCR using two-sided 2 or Fisher's exact test. Disease-free (DFS) and overall survival (OS) were calculated from date of registration to local or distant invasive relapse, death, or last follow-up and plotted as Kaplan-Meier curves. Log-rank P values were calculated for different pCR definitions and residual disease scores. Hazard ratios (HRs), 95% CIs, and corresponding P values between categorized score values were calculated using Cox regression analysis. Prognostic information of the residual disease scores was compared in a Cox regression model. This test was also used with pCR as categorized covariate to determine the prognostic impact of pCR in various subgroups. Cox regression models were conducted as full models including all factors in the final model regardless of their statistical significance; dummy variables were used for categorized covariates, and patients with missing values for any factor were excluded from these analyses. SPSS 14.0 (SPSS, Chicago, IL) was used to perform all analyses. the setting of seven randomized clinical trials (Appendix Table A1 , online only). During a median follow-up of 46.3 months (range, 0 to 127 months) and observation of 22.869 patient years, 1,466 relapses (23%) and 775 deaths (12.2%) were observed. Median age of patients at time of study entry was 50.1 years (range, 21 to 81 years); median tumor size was 4.0 cm (range, 1.2 to 33.0 cm); 5,618 patients had operable and 759 had locally advanced breast cancer. Tumors stained positive for ER in 3,771 (60.4%) and for (Table 1) .
Correlation Between pCR Rate and Outcome
Stage ypT0 ypN0 was diagnosed in 955 (15.0%), ypTis ypN0 in 309 (4.8%), ypT0/is ypNϩ in 186 (2.9%), ypT1mic ypN0/ϩ in 478 (7.5%), and ypTϾ1mic ypN0/ϩ in 4,449 patients (69.8%). Prognosis differed between components of pCR definition (DFS: P Ͻ .001; OS: P Ͻ .001; Figs 1A and 1B). Patients with ypT0 ypN0 tumors experienced better DFS compared with patients with ypTis ypN0 tumors (HR, 1.74; 95% CI, 1.28 to 2.36; P Ͻ .001) and showed a trend toward better OS (HR, 1.41; 95% CI, 0.87 to 2.29; P ϭ .166). Their prognosis was also better than that of patients with ypT0/is ypNϩ (DFS: HR, 3.18; 95% CI, 2.31 to 4.38; P Ͻ .001; OS: HR, 4.05; 95% CI, 2.63 to 6.24; P Ͻ .001) or ypT1mic ypN0/ϩ tumors (DFS: HR, 2.33; 95% CI, 1.81 to 3.01; P Ͻ .001; OS: HR, 2.34; 95% CI, 1.61 to 3.41; P Ͻ .001; Table 2 ). Patients with stage ypT0/is ypNϩ tumors experienced the worst DFS and OS (Figs 1A and 1B) . HR for DFS comparing Log-rank P < .001
Log-rank P < .001
Log-rank P < .001 patients with or without pCR according to the various pCR definitions was highest for ypT0 ypN0 (4.04) and decreased monotonously for ypT0/is ypN0 (3.51), ypT0/is ypN0/ϩ (2.77), and ypT0/ is/mic ypN0/ϩ (2.11).
Correlation Between Residual Disease Score and Outcome
Overall, histologic breast RS significantly correlated with DFS and OS (P Ͻ .001). Patients with noninvasive residuals only did not experience a significantly different outcome compared with those with focal-invasive residuals or minimal or no signs of regression ( Table 2 ; Figs 1C and 1D ). Tumor stage after neoadjuvant chemotherapy (ypT) was significantly associated with prognosis (P Ͻ .001; Figs 1E and 1F), especially for patients with ypT3, ypT4a-c, and ypT4 disease, who had the worst outcome ( Table 2) . Comparable results were observed for nodal stage ypN. Patients with ypN2 and ypN3 disease had a median DFS of 70 and 30 months, respectively ( Table 2 ; Figs 1G and 1H) . A multivariate Cox regression model showed that all three residual disease scores provided independent prognostic information (Appendix Table A2 , online only).
Prognostic Information of pCR in Various Subpopulations
For the following analysis, pCR was defined as ypT0 ypN0 showing the lowest HR comparing patients with or without pCR. pCR seemed to predict a more favorable outcome independent of age, . However, in patients achieving pCR, prognosis was not significantly different for the intrinsic subtypes (DFS: P ϭ .055; OS: P ϭ .70). In fact, DFS of patients with HER2-positive and TN tumors was better than that of those with luminal B/HER2-positive tumors (P Ͻ .02; Fig 2F) .
DISCUSSION
This is, to the best of our knowledge, the first individual patient-based pooled analysis analyzing different pCR definitions for their prognostic impact on survival of patients with breast cancer treated with neoadjuvant anthracycline-taxane-based chemotherapy. The large patient collective included sufficient subpopulations with small residual disease volume (eg, noninvasive residuals only, focal-invasive disease Ͻ 5 mm, or no invasive tumor in the breast but involved lymph nodes). Over the last decades, these subpopulations have frequently been considered to have achieved pCR. However, we show that these subpopulations have an increased risk of relapse and sometimes of death as well compared with the group of patients with stage ypT0 ypN0 breast cancer. pCR restricted to this stage showed the lowest adjusted HR for DFS and OS compared with the other definitions ( Table 2 ). We further demonstrate that in subgroups considered to have slowly proliferating tumors, pCR is not associated with prognosis, whereas in subgroups with highly proliferating tumors, pCR can dis-criminate between patients with good and poor prognosis accurately. The recently proposed clinicopathologic definition of the St Gallen panel nicely recognizes these subgroups. In fact, prognostic impact of pCR is highest in HER2-positive (nonluminal) and TN tumors, where patients achieving pCR show a prognosis comparable to that of patients with luminal A tumors.
Surprisingly, pCR was not prognostic in the luminal B/HER2positive subgroup irrespective of trastuzumab treatment. In this subgroup, pCR rates were low, despite concomitant anti-HER2 therapies, 11,28,29 but similar outcomes were observed in the adjuvant trastuzumab studies. 30 Inclusion of noninvasive residuals in the pCR definition has been mainly supported by the hitherto largest analysis of the MD Anderson group of 2,302 patients, showing no difference in DFS or OS between patients with ypT0 ypN0 and ypTis ypN0 tumors. 31 However, the number of patients with ypT0 ypN0 (n ϭ 199) and ypTis ypN0 (n ϭ 78) tumors was much lower than in our analysis, resulting in a much lower statistical power to show prognostic differences. This may be attributed to less intense neoadjuvant treatment, resulting in lower pCR rates. Only 42% of patients received a combination of anthracyclines and taxanes. 31 Other analyses have failed to show correlation betweendifferentpCRdefinitionsandoutcome,possiblybecauseofsmall sample sizes. 32, 33 Another argument for inclusion of low-volume residual diseaseinthepCRdefinitionhascomefrombiomarkerstudies.Inthecase of low pCR rates, these studies become severely underpowered. However, the more active treatments used today result in pCR rates of 20% to 40%, rendering this argument moot.
We could not assess other pCR scores (eg, residual cancer burden, 34 grading by Miller-Payne 35 ). However, we suggest that a more thorough comparison of all these scores is necessary to decide whether more extensive pathologic assessments are necessary.
The prognostic importance of involved lymph nodes after neoadjuvant chemotherapy has already been stressed by others. 36,37 However, withthelargesamplesize,wecannowdemonstratethatthesmallgroupof patients with ypT0/is ypNϩtumors has a considerably inferior prognosis, comparable to that of patients with tumor residuals in breast and nodes.
The strengths of this pooled analysis are the large sample size and considerable number of patient years available. All patients participated in prospective trials, receiving comparable anthracycline-taxane-containing neoadjuvant regimens under homogenous national treatment conditions. Although some parameters were incomplete, this data set is currently unique because of the availability of HER2 status. Weaknesses of this analysis are the unavailability of Ki-67 to measure proliferation, the imprecise categorization of breast cancer subtypes because of the lack of gene profiles, and the lack of central assessment of surgical specimens. Because of this, it is possible that the poorer outcome of patients with residual ductal carcinoma in situ could have been the result of invasive parts not being detected because of insufficient histopathologic examination.
We conclude that pCR defined as ypT0 ypN0 is associated with highly favorable outcome. ypTis, ypT1mic, and ypNϩ residuals only are associated with increased relapse risk and should therefore no longer be considered as pCR. Extent of residual disease and evidence of regression provide helpful additional prognostic information. pCR is a suitable surrogate end point for patients with HER2-positive (nonluminal), TN, and luminal B/HER2-negative tumors but not for luminal B/HER2-positive and luminal A tumors.
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